Cargando…

The Role and Therapeutic Targeting of CCR5 in Breast Cancer

The G-protein-coupled receptor C-C chemokine receptor 5 (CCR5) functions as a co-receptor for the entry of HIV into immune cells. CCR5 binds promiscuously to a diverse array of ligands initiating cell signaling that includes guided migration. Although well known to be expressed on immune cells, rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamid, Rasha, Alaziz, Mustafa, Mahal, Amanpreet S., Ashton, Anthony W., Halama, Niels, Jaeger, Dirk, Jiao, Xuanmao, Pestell, Richard G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526962/
https://www.ncbi.nlm.nih.gov/pubmed/37759462
http://dx.doi.org/10.3390/cells12182237
_version_ 1785111105614381056
author Hamid, Rasha
Alaziz, Mustafa
Mahal, Amanpreet S.
Ashton, Anthony W.
Halama, Niels
Jaeger, Dirk
Jiao, Xuanmao
Pestell, Richard G.
author_facet Hamid, Rasha
Alaziz, Mustafa
Mahal, Amanpreet S.
Ashton, Anthony W.
Halama, Niels
Jaeger, Dirk
Jiao, Xuanmao
Pestell, Richard G.
author_sort Hamid, Rasha
collection PubMed
description The G-protein-coupled receptor C-C chemokine receptor 5 (CCR5) functions as a co-receptor for the entry of HIV into immune cells. CCR5 binds promiscuously to a diverse array of ligands initiating cell signaling that includes guided migration. Although well known to be expressed on immune cells, recent studies have shown the induction of CCR5 on the surface of breast cancer epithelial cells. The function of CCR5 on breast cancer epithelial cells includes the induction of aberrant cell survival signaling and tropism towards chemo attractants. As CCR5 is not expressed on normal epithelium, the receptor provides a potential useful target for therapy. Inhibitors of CCR5 (CCR5i), either small molecules (maraviroc, vicriviroc) or humanized monoclonal antibodies (leronlimab) have shown anti-tumor and anti-metastatic properties in preclinical studies. In early clinical studies, reviewed herein, CCR5i have shown promising results and evidence for effects on both the tumor and the anti-tumor immune response. Current clinical studies have therefore included combination therapy approaches with checkpoint inhibitors.
format Online
Article
Text
id pubmed-10526962
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105269622023-09-28 The Role and Therapeutic Targeting of CCR5 in Breast Cancer Hamid, Rasha Alaziz, Mustafa Mahal, Amanpreet S. Ashton, Anthony W. Halama, Niels Jaeger, Dirk Jiao, Xuanmao Pestell, Richard G. Cells Review The G-protein-coupled receptor C-C chemokine receptor 5 (CCR5) functions as a co-receptor for the entry of HIV into immune cells. CCR5 binds promiscuously to a diverse array of ligands initiating cell signaling that includes guided migration. Although well known to be expressed on immune cells, recent studies have shown the induction of CCR5 on the surface of breast cancer epithelial cells. The function of CCR5 on breast cancer epithelial cells includes the induction of aberrant cell survival signaling and tropism towards chemo attractants. As CCR5 is not expressed on normal epithelium, the receptor provides a potential useful target for therapy. Inhibitors of CCR5 (CCR5i), either small molecules (maraviroc, vicriviroc) or humanized monoclonal antibodies (leronlimab) have shown anti-tumor and anti-metastatic properties in preclinical studies. In early clinical studies, reviewed herein, CCR5i have shown promising results and evidence for effects on both the tumor and the anti-tumor immune response. Current clinical studies have therefore included combination therapy approaches with checkpoint inhibitors. MDPI 2023-09-08 /pmc/articles/PMC10526962/ /pubmed/37759462 http://dx.doi.org/10.3390/cells12182237 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Hamid, Rasha
Alaziz, Mustafa
Mahal, Amanpreet S.
Ashton, Anthony W.
Halama, Niels
Jaeger, Dirk
Jiao, Xuanmao
Pestell, Richard G.
The Role and Therapeutic Targeting of CCR5 in Breast Cancer
title The Role and Therapeutic Targeting of CCR5 in Breast Cancer
title_full The Role and Therapeutic Targeting of CCR5 in Breast Cancer
title_fullStr The Role and Therapeutic Targeting of CCR5 in Breast Cancer
title_full_unstemmed The Role and Therapeutic Targeting of CCR5 in Breast Cancer
title_short The Role and Therapeutic Targeting of CCR5 in Breast Cancer
title_sort role and therapeutic targeting of ccr5 in breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526962/
https://www.ncbi.nlm.nih.gov/pubmed/37759462
http://dx.doi.org/10.3390/cells12182237
work_keys_str_mv AT hamidrasha theroleandtherapeutictargetingofccr5inbreastcancer
AT alazizmustafa theroleandtherapeutictargetingofccr5inbreastcancer
AT mahalamanpreets theroleandtherapeutictargetingofccr5inbreastcancer
AT ashtonanthonyw theroleandtherapeutictargetingofccr5inbreastcancer
AT halamaniels theroleandtherapeutictargetingofccr5inbreastcancer
AT jaegerdirk theroleandtherapeutictargetingofccr5inbreastcancer
AT jiaoxuanmao theroleandtherapeutictargetingofccr5inbreastcancer
AT pestellrichardg theroleandtherapeutictargetingofccr5inbreastcancer
AT hamidrasha roleandtherapeutictargetingofccr5inbreastcancer
AT alazizmustafa roleandtherapeutictargetingofccr5inbreastcancer
AT mahalamanpreets roleandtherapeutictargetingofccr5inbreastcancer
AT ashtonanthonyw roleandtherapeutictargetingofccr5inbreastcancer
AT halamaniels roleandtherapeutictargetingofccr5inbreastcancer
AT jaegerdirk roleandtherapeutictargetingofccr5inbreastcancer
AT jiaoxuanmao roleandtherapeutictargetingofccr5inbreastcancer
AT pestellrichardg roleandtherapeutictargetingofccr5inbreastcancer